SG10202007262PA - Copanlisib biomarkers - Google Patents

Copanlisib biomarkers

Info

Publication number
SG10202007262PA
SG10202007262PA SG10202007262PA SG10202007262PA SG10202007262PA SG 10202007262P A SG10202007262P A SG 10202007262PA SG 10202007262P A SG10202007262P A SG 10202007262PA SG 10202007262P A SG10202007262P A SG 10202007262PA SG 10202007262P A SG10202007262P A SG 10202007262PA
Authority
SG
Singapore
Prior art keywords
copanlisib
biomarkers
copanlisib biomarkers
Prior art date
Application number
SG10202007262PA
Other languages
English (en)
Inventor
Li Liu
Carol Pena
Jie Cheng
Karl Köchert
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG10202007262PA publication Critical patent/SG10202007262PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10202007262PA 2016-02-01 2017-01-30 Copanlisib biomarkers SG10202007262PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662289713P 2016-02-01 2016-02-01
US201662376017P 2016-08-17 2016-08-17

Publications (1)

Publication Number Publication Date
SG10202007262PA true SG10202007262PA (en) 2020-09-29

Family

ID=57984901

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007262PA SG10202007262PA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers
SG11201806274SA SG11201806274SA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201806274SA SG11201806274SA (en) 2016-02-01 2017-01-30 Copanlisib biomarkers

Country Status (16)

Country Link
US (1) US20190038632A1 (fr)
EP (1) EP3411497A1 (fr)
JP (1) JP2019511204A (fr)
KR (1) KR20180101603A (fr)
CN (1) CN108884496A (fr)
AU (1) AU2017214230A1 (fr)
BR (1) BR112018015782A2 (fr)
CA (1) CA3012890A1 (fr)
CL (1) CL2018002069A1 (fr)
MA (1) MA43957A (fr)
MX (1) MX2018009368A (fr)
PH (1) PH12018501623A1 (fr)
SG (2) SG10202007262PA (fr)
SV (1) SV2018005730A (fr)
TN (1) TN2018000271A1 (fr)
WO (1) WO2017134000A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018127A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
MX2017011635A (es) 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
WO2017153220A1 (fr) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US10925880B2 (en) 2016-09-23 2021-02-23 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
HUE063178T2 (hu) * 2017-09-08 2023-12-28 Bayer Pharma AG Kopanlizib formulációi
WO2020092860A1 (fr) * 2018-11-01 2020-05-07 The Jackson Laboratory Traitements du cancer gastrique
EP4231872A1 (fr) 2020-10-21 2023-08-30 Black Jet Innovations, Inc. Poignée et support de dispositif mobile

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
SG11201507265XA (en) * 2013-04-08 2015-10-29 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
HUE053611T2 (hu) * 2013-06-20 2021-07-28 Taiho Pharmaceutical Co Ltd Eljárás PI3K/AKT/mTOR inhibitor terápiás hatékonyságának elõrejelzésére PHLDA1 vagy PIK3C2B expressziója alapján
CN106661614A (zh) * 2014-03-11 2017-05-10 昆士兰医学研究所理事会 确定癌症侵袭性、预后和治疗响应
WO2015160986A2 (fr) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
CN108884496A (zh) 2018-11-23
AU2017214230A1 (en) 2018-08-09
CL2018002069A1 (es) 2018-11-16
US20190038632A1 (en) 2019-02-07
WO2017134000A1 (fr) 2017-08-10
CA3012890A1 (fr) 2017-08-10
BR112018015782A2 (pt) 2019-01-02
SV2018005730A (es) 2018-12-05
EP3411497A1 (fr) 2018-12-12
PH12018501623A1 (en) 2019-06-03
TN2018000271A1 (en) 2020-01-16
MA43957A (fr) 2018-12-12
SG11201806274SA (en) 2018-08-30
KR20180101603A (ko) 2018-09-12
JP2019511204A (ja) 2019-04-25
MX2018009368A (es) 2018-09-05

Similar Documents

Publication Publication Date Title
AU201616678S (en) Cylindres
GB2566681B (en) Biomarker
GB201420908D0 (en) Biomarkers
SG10202007262PA (en) Copanlisib biomarkers
GB201401603D0 (en) Biomarkers
SG10202007322PA (en) Copanlisib biomarkers
GB201614455D0 (en) Biomarkers
GB201500584D0 (en) Cancer biomarkers
ZA202001821B (en) Biomarker
GB201703058D0 (en) Biomarkers
GB201704267D0 (en) Novel biomarker
GB201404189D0 (en) Novel biomarkers
GB201710858D0 (en) Biomarker
GB201500729D0 (en) Novel Biomarkers
GB201703123D0 (en) Biomarkers
ZA201804709B (en) Tb biomarkers
GB201416015D0 (en) Biomarker
GB201512133D0 (en) Biomarkers
GB201420239D0 (en) Biomarker
GB201720776D0 (en) Biomarkers
GB201706669D0 (en) Biomarkers
GB201702986D0 (en) Biomarkers
GB201707113D0 (en) Biomarker
GB201519704D0 (en) Biomarkers
GB201513683D0 (en) Biomarkers